While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers. In a new draft guidance, the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing. The agency through a separate initiative also plans to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, helping patients and pharmacists choose lower-cost options more easily.
Rising tensions in the Middle East following attacks by the US and Israel on Iran are expected to disrupt trade flows, push up freight and insurance costs, delay cargo shipments, and drive a surge in global oil prices.
Air routes are being altered, and maritime trade through the Red Sea and key Gulf straits face heightened uncertainty. If diversions become prolonged, shipments may increasingly have to reroute via the Cape of Good Hope, adding an estimated 15-20 days to transit time for Europe and the United States.
The Strait of Hormuz is considered the world’s most strategically important oil transit bottleneck, according to the US Energy Information Administration (EIA). Such chokepoints are narrow maritime corridors along key global shipping lanes through which large volumes of energy supplies move every day. Any disruption, even temporary, can delay cargoes, drive up freight and insurance costs, and trigger spikes in international oil prices. While tankers can sometimes reroute, alternative passages typically involve longer sailing times and higher expenses. In certain cases, there are no viable substitutes. In the same neighbourhood, the Bab el-Mandeb strait, which connects the Red Sea to the Gulf of Aden, is already facing pressure from attacks by Yemen’s Houthi movement.
Middle East tensions raise supply chain, logistics cost concerns for India Inc
Rising Tensions in Middle East May Impact Trade, Push Up Freight, Insurance Costs – Outlook Business
Israel-Iran war’s ‘Strait’ fight can damage one of India’s well-built firewalls – The Economic Times
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Choline salicylate is a salicylate salt formed from choline and salicylic acid. It is a non-steroidal anti-inflammatory agent (NSAID-type compound) mainly used for its analgesic, anti-inflammatory, and mild antiseptic properties. Unlike acetylated salicylates, it is less irritating to the gastric mucosa and is commonly used in topical oral preparations such as gels and mouth paints.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
TensyraTM N-10 (Octoxinol 10; tert-octyl phenyl ethoxylate) is a non-ionic surfactant known for its excellent solubilizing and membrane-permeabilizing properties. It features a hydrophilic polyethylene oxide chain paired with a lipophilic aromatic hydrocarbon group.It readily breaks down biological membranes to lyse cells, solubilize proteins, and permeabilize cell membranes for assays.